Bladder Cancer Clinical Trials

322 recruitingLast updated: June 17, 2026

There are 322 actively recruiting bladder cancer clinical trials across 46 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4. Top locations include New York, New York, United States, Dallas, Texas, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Bladder Cancer Trials at a Glance

322 actively recruiting trials for bladder cancer are listed on ClinicalTrialsFinder across 6 cities in 46 countries. The largest study group is Phase 2 with 93 trials, with the heaviest enrollment activity in New York, Dallas, and Houston. Lead sponsors running bladder cancer studies include National Cancer Institute (NCI), Memorial Sloan Kettering Cancer Center, and Cedars-Sinai Medical Center.

Browse bladder cancer trials by phase

Treatments under study

About Bladder Cancer Clinical Trials

Looking for clinical trials for Bladder Cancer? There are currently 200 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Bladder Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Bladder Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 322 trials

Recruiting

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Bladder CancerKidney CancerRenal Cancer+2 more
National Cancer Institute (NCI)5,950 enrolled1 locationNCT00026884
Recruiting
Phase 2

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Stage I Bladder Cancer AJCC v8Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
National Cancer Institute (NCI)160 enrolled133 locationsNCT06770582
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled578 locationsNCT03866382
Recruiting

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

Bladder Cancer
National Cancer Institute (NCI)25 enrolled1 locationNCT04235764
Recruiting
Phase 1Phase 2

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

Advanced Bladder Cancer
M.D. Anderson Cancer Center41 enrolled1 locationNCT06434350
Recruiting

Impact of COMORBIDities After Radical Cystectomy Using a Predictive Method With Artificial Intelligence

Bladder CancerDeep LearningComorbidity
Centre Hospitalier Universitaire, Amiens500 enrolled1 locationNCT05204186
Recruiting
Phase 2Phase 3

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Urothelial CancerBladder Cancer
Daiichi Sankyo630 enrolled100 locationsNCT07129993
Recruiting
Phase 1Phase 2

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Non Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC32 enrolled13 locationsNCT06637423
Recruiting
Phase 2

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
National Cancer Institute (NCI)111 enrolled143 locationsNCT07061964
Recruiting
Phase 2

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

Metastatic Malignant Solid NeoplasmMetastatic Bladder Urothelial CarcinomaMTAP Deletion+1 more
Northwestern University64 enrolled2 locationsNCT06630416
Recruiting

Evaluation for NCI Surgery Branch Clinical Research Protocols

Colorectal, CancerLung CancerMelanoma+2 more
National Cancer Institute (NCI)7,000 enrolled1 locationNCT00001823
Recruiting
Phase 2

EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC

Muscle Invasive Bladder Cancer (MIBC)
Peking University Third Hospital58 enrolled1 locationNCT07647289
Recruiting
Phase 2

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer

Non-Muscle-Invasive Bladder Cancer (NMIBC)
Shanxi Province Cancer Hospital30 enrolled1 locationNCT07646145
Recruiting
Not Applicable

A Study of a Side Effects and Resource Navigation Program for People With Cancer

Breast CancerLung CancerBladder Cancer+1 more
Memorial Sloan Kettering Cancer Center200 enrolled8 locationsNCT07646847
Recruiting
Phase 1Phase 2

DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr

Bladder Cancer
University College, London52 enrolled7 locationsNCT04106115
Recruiting

Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy

Bladder CancerNon Muscle Invasive Bladder Cancer
Photocure500 enrolled4 locationsNCT07144319
Recruiting
Not Applicable

Local Radiotherapy for Urinary Bladder Cancer in Patients Not Eligible for Curative Treatment

Bladder Cancer (BC)
Umeå University248 enrolled1 locationNCT07524426
Recruiting
Phase 1

Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

Urothelial CancerBladder CancerGenitourinary Cancer+2 more
National Cancer Institute (NCI)100 enrolled1 locationNCT04235777
Recruiting

A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies

Urothelial CancerBladder CancerGenitourinary Cancer+2 more
National Cancer Institute (NCI)1,100 enrolled1 locationNCT04923178
Recruiting
Phase 2

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Muscle Invasive Bladder Cancer
Astellas Pharma Global Development, Inc.240 enrolled9 locationsNCT07475806